Bimekizumab safe and effective for treatment of moderate-to-severe hidradenitis suppurative
1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse ...
Tag: Hidradenitis suppurativa
Intravenous ertapenem for hidradenitis suppurativa
1. Intravenous ertapenem administered for a mean of 13 weeks for patients with hidradenitis suppurativa was associated with improvement in ...
Healthcare Barriers and Hidradenitis Suppurativa: The Patient Experience
1. Patients with hidradenitis suppurativa (HS) experience compounding healthcare barriers related to disease activity, employment, healthcare coverage, costs, healthcare professionals’ ...
#VisualAbstract: Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated, ...
Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated, ...
#VisualAbstract: Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa
1. Adalimumab was efficacious when used simultaneously with wide-excision surgery for treatment of moderate to severe hidradenitis suppurativa (HS). Evidence ...
New prevalence estimates for hidradenitis suppurativa in the United States
1. In a population-based analysis of over 48 million records in the United States (US), the overall prevalence of hidradenitis ...
Hidradenitis suppurativa associated with increased risk of subclinical atherosclerosis
1. In a prospective study of 62 patients with hidradenitis suppurativa (HS) and their matched controls, HS was associated with ...